Pathogenic Gram-negative bacteria use syringe-like type III secretion systems (T3SS) to inject effector proteins directly into targeted host cells. Effector secretion is triggered by host cell contact, and before contact is prevented by a set of conserved regulators. How these regulators interface with the T3SS apparatus to control secretion is unclear. We present evidence that the proton motive force (pmf) drives T3SS secretion in Pseudomonas aeruginosa, and that the cytoplasmic regulator PcrG interacts with distinct components of the T3SS apparatus to control two important aspects of effector secretion: (i) It coassembles with a second regulator (Pcr1) on the inner membrane T3SS component PcrD to prevent effectors from accessing the T3SS, and (ii) In conjunction with PscO, it controls protein secretion activity by modulating the ability of T3SS to convert pmf.
Pathogenic Gram-negative bacteria use syringe-like type III secretion systems (T3SS) to inject effector proteins directly into targeted host cells. Effector secretion is triggered by host cell contact, and before contact is prevented by a set of conserved regulators. How these regulators interface with the T3SS apparatus to control secretion is unclear. We present evidence that the proton motive force (pmf) drives T3SS secretion in Pseudomonas aeruginosa, and that the cytoplasmic regulator PcrG interacts with distinct components of the T3SS apparatus to control two important aspects of effector secretion: (i) It coassembles with a second regulator (Pcr1) on the inner membrane T3SS component PcrD to prevent effectors from accessing the T3SS, and (ii) In conjunction with PscO, it controls protein secretion activity by modulating the ability of T3SS to convert pmf.
M
any Gram-negative bacterial pathogens rely on a type III secretion system (T3SS) to promote disease by directly injecting effector proteins into the cytoplasm of host cells. This apparatus consists of a base that spans the bacterial envelope and a needle that projects from the base and ends in a specialized tip structure. The bacterium secretes two translocator proteins via the T3SS, which insert into the host cell membrane to form a pore, through which effector proteins are then transferred (1, 2).
One of the hallmarks of type III secretion is that export of effector proteins is triggered by host cell contact (3) (4) (5) . The secretion apparatus is fully assembled before cell contact, but effector secretion is prevented through the concerted action of needle tip-associated proteins and regulators that control secretion from the bacterial cytoplasm.
In most systems, the needle tip protein prevents premature effector secretion, most likely by allosterically constraining the T3SS in an effector secretion "off" conformation (6) (7) (8) (9) (10) . PcrG, the needle tip protein chaperone, as well as PopN, a member of the YopN/MxiC family of proteins, control effector secretion from the bacterial cytoplasm in Pseudomonas aeruginosa. PcrG's regulatory function is independent of its function in promoting the export of needle tip protein PcrV. Deletion of pcrG or pcrV results in partial deregulation of effector secretion, whereas removal of both genes results in high-level secretion of effectors (8) . In some bacteria, the needle tip protein promotes its own export with the aid of a self-chaperoning domain, rather than with a separate export chaperone (11) . Recent evidence suggests that in these systems, the needle tip protein itself also regulates effector secretion from the cytoplasm, in addition to its regulatory role at the T3SS needle tip (12) . The mechanism of this regulation is unclear.
YopN/MxiC family proteins, PopN in P. aeruginosa, are T3SS regulators that are exported once effector secretion is triggered (13) (14) (15) (16) (17) . These proteins control effector secretion from the bacterial cytoplasm (18) (19) (20) . P. aeruginosa PopN and the closely related YopN associate with three other proteins that are required to prevent premature effector secretion (21-23). For PopN, these three proteins are Pcr1, Pcr2, and PscB. Pcr2 and PscB form a heterodimeric export chaperone, and Pcr1 is thought to tether the PopN complex to the apparatus (23). The prevailing model for explaining how PopN and related regulators control effector secretion is that they partially insert and plug the secretion channel while being tethered to the T3SS, either directly via a C-terminal interaction or indirectly via a C-terminalassociated protein, i.e., Pcr1 in P. aeruginosa (19, 20) . The apparatus component with which these regulators interact is unknown, however.
Triggering of effector secretion results in the rapid injection of effector proteins into the host cell (4, 5) . How this rapid burst of secretion is energized is a matter of some controversy. The flagellum, which also uses a type III secretion mechanism, uses the proton motive force (pmf) to catalyze the rapid export of flagellar subunits. In fact, secretion is possible in mutants lacking the flagellum-associated ATPase, FliI, if the associated regulatory protein, FliH, is eliminated as well (24-26). The pmf's contribution to the rate of secretion relative to the ATPase has been questioned in the case of virulence-associated T3SS (27), where removal of the ATPase results in a complete block of secretion (28, 29) that is not alleviated by deletion of the associated FliH homolog (30).
Here we present evidence that export via the P. aeruginosa T3SS is energized primarily by the pmf, thereby offering a unified model for how protein secretion is energized in all T3SSs. The cytoplasmic T3SS regulator PcrG controls both the access of effectors to the T3SS and, surprisingly, the secretion activity of the apparatus. These two functions are controlled by separate regions of PcrG. Control of secretion activity involves the central portion of PcrG as well as PscO, which regulate the pmfdependent export of secretion substrates. Mutants that up-regulate translocator secretion without turning on effector export confirm that effector secretion is not blocked by physical obstruction of Significance Type III secretion systems (T3SSs) are nanomachines used by pathogenic bacteria to directly inject effector proteins into host cells and thereby promote disease. Effector secretion is actively prevented until it is triggered by host cell contact. We have determined how cytoplasmic regulators that prevent premature effector secretion interact with the apparatus to block effectors from accessing T3SS. We also demonstrate that the burst of secretion observed when effector secretion is triggered consists of two genetically separable components: access of effectors to the T3SS and a change in secretion activity. The latter is achieved by modulating the ability of the T3SS to convert proton motive force into protein export.
the secretion channel. Instead, access of effectors to the T3SS is controlled by the C terminus of PcrG in conjunction with the PopN complex through an interaction with the inner membrane T3SS component PcrD. This protein complex likely blocks an acceptor site for effectors. Thus, PcrG is a multifaceted protein that, along with its export chaperone function, serves as a brake and a switch to control effector secretion.
Results
PcrG Controls Both Secretion Activity and Specificity of the Type III Secretion Apparatus. Our previous analysis demonstrated that the N-terminal 40 amino acids of PcrG are sufficient to bind to PcrG's cognate export substrate, PcrV, but have no regulatory role. In contrast, the C-terminal 45 amino acids of PcrG are sufficient to restore effector secretion control to near-WT levels in a pcrG null mutant strain (8) . To characterize the regulatory activity of the C-terminal portion of PcrG further and identify residues that could be involved in contacting the apparatus, we analyzed the ability of truncated versions of PcrG, as well as of point mutants affecting a subset of conserved residues in the C terminus of the protein (Fig. 1A) , to control effector secretion.
Point mutants and truncated versions of pcrG were fused to a version of malE that encodes a signal sequence-less maltosebinding protein (MBP), and then assayed for their ability to complement a pcrG deletion strain. Production of the MBPPcrG fusion proteins was confirmed by Western blot analysis (Fig. 1B) . Fusion of PcrG to the C terminus of MBP helps stabilize fragments of PcrG that otherwise would be rapidly degraded (8) . To assay effector secretion control, we made use of a feature of the P. aeruginosa system whereby triggering of effector secretion results in up-regulation of T3SS gene expression owing to export of the negative regulator ExsE via the T3SS (31, 32). Thus, the triggering of effector secretion by removal of calcium from the medium or by cell contact can be assayed using a transcriptional reporter of effector gene expression, in our case exoS.
WT MBP-PcrG was fully functional and prevented triggering of effector secretion in the presence of calcium, as assayed using the exoS-lacZ reporter system (Fig. 1C) . PcrG lacking the C-terminal 25 amino acids, PcrG(Δ71-95), was inactive, whereas the converse fusion, PcrG(Δ1-59), partially restored effector secretion control (Fig. 1C) . PcrG(R85E/R86E), PcrG(M90A/ R91A/G92A), and PcrG(I95E) were at least partially defective in terms of preventing effector secretion in the presence of calcium, highlighting the importance of the C terminus for effector secretion control.
To assess effector secretion control directly, and also to assay the effect of our pcrG mutations on the export of translocator proteins, which are secreted before effector secretion is triggered, we performed secretion assays in a ΔexsE ΔpcrG mutant strain background. Deletion of exsE results in constitutive, highlevel expression of the T3SS and its substrates and minimizes the effect of changes in T3SS activation on gene expression and protein levels (31). A ΔexsE mutant strain assembles an equal number of secretion apparatuses in both the presence and absence of calcium (SI Appendix, Fig. S1 ). Effector secretion is still tightly regulated and has to be triggered, either by removing calcium from the medium or by cell contact (31, 32). We also removed fleQ, the master regulator of flagellar gene expression, to eliminate residual secretion of substrates via the flagellar T3SS. Removal of pcrG in the ΔexsE strain resulted in elevated secretion of both effectors and translocators ( Fig. 1 D and E) . Production of WT PcrG, as well as PcrG(A16R), which is unable to bind to PcrV (8) , prevented effector secretion in the presence (A) PcrG of P. aeruginosa PAO1 and homologs from Y. pseudotuberculosis YPIII and A. hydrophila AH3 were aligned using ClustalW (accession nos.: PcrG, AAG05094.1; LcrG, AAA27644.1; AcrG, AAS91818.1). Identical (dark gray) and similar (light gray) residues are indicated. PcrG point mutants (red asterisk) and truncations fused to MBP and assayed in B are shown below. (B) Production of MBP-PcrG fusion proteins was assayed in strain PAO1F ΔpcrG ΔexoS::GFP-lacZ, complemented with the indicated malE-pcrG fusions and induced with 10 μM isopropyl β-D-1-thiogalactopyranoside (IPTG). (C) Control of effector secretion with and without calcium was analyzed by the β-galactosidase assay using the same strain background and IPTG concentration. Statistical significance of differences compared with the vector control is noted. **P < 0.01, Student t test. (D) PAO1F ΔexsE ΔfleQ ΔpcrG producing the indicated MBP-PcrG fusion protein (induced with 25 μM IPTG) was grown in the presence of calcium. Cell pellet and supernatant samples were probed with antibodies against effector proteins (ExoS and ExoT) or translocator proteins (PopB and PopD). RpoA served as a fractionation control. (E) Three independent secretion assays were quantitated. The secretion efficiency (i.e., supernatant protein/total protein) in strains producing the indicated MBP-PcrG fusions was determined for each protein by quantitating the band intensities and normalizing secretion to the ΔpcrG parent strain (set to 100%). Statistical significance of differences relative to vector control was determined for combined translocator secretion (black asterisk) or effector secretion (red asterisk). **P < 0.01, Student t test.
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The Central Portion of PcrG Controls Secretion Activity. Because PcrG is not secreted, it must control effector secretion by interacting with a cytoplasmic or inner membrane component of the T3SS. We identified potential binding partners for PcrG using a bacterial two-hybrid system (33). PcrG was fused to λ cI, and potential interaction partners were fused to the RNA polymerase α-subunit. Interaction results in cI-PcrG-dependent recruitment of RNA polymerase to a test promoter driving β-galactosidase expression. PcrG interacts more strongly with PscO than with any other cytoplasmic T3SS component in this assay (SI Appendix, Fig. S2A ). PscO is homologous to the flagellar protein FliJ, which was recently linked to the pmf-dependent export of flagellar subunits (26).
To determine whether the interaction of PcrG with PscO involves the C-terminal 35 amino acids of PcrG that are important for effector secretion control ( Fig. 1 C and E) , we mapped the interaction by deletion analysis using the two-hybrid system. Residues 2-70 of PcrG were sufficient to bind to PscO in this assay, indicating that this interaction does not involve the C-terminal 25 amino acids of PcrG. Deletion of amino acids 1-20, 1-30, or 1-40 of PcrG progressively diminished binding to PscO; however, amino acids 2-40 of PcrG were not sufficient to allow binding to PscO, arguing that recognition of PscO involves the central portion of PcrG. Indeed, deletion of residues 30-40 and 60-70 of PcrG [PcrG(Δ30-40,Δ60-70)] resulted in a protein that can still interact with PcrV, but fails to bind to PscO ( Fig.  2A) . This result was confirmed by coprecipitation of proteins produced recombinantly in Eshcerichia coli. PcrG and PcrG(Δ71-95), but not PcrG(Δ30-40,Δ60-70), were able to coprecipitate a Myc-tagged version of PscO (SI Appendix, Fig. S2B ). Binding of PcrG to PscO involves the central portion of PcrG and likely is not responsible for specificity control. Indeed, pcrG(Δ30-40, Δ60-70) was able to complement a pcrG null mutant to near-WT levels with regard to preventing effector secretion in the presence of calcium (Fig. 2B) .
We next analyzed the ability of PcrG(Δ30-40,Δ60-70) to control translocator export in the ΔexsE mutant background. In the presence of calcium, export of the PopB, PopD, and PcrV translocator proteins was up-regulated relative to WT (Fig. 2C ). In contrast, the level of effector export was significantly reduced compared with the pcrG null mutant strain (vector control) when providing PcrG(Δ30-40,Δ60-70). This phenotype closely mirrors the secretion phenotype seen when expressing PcrG(Δ1-59) ( Fig.  1 D and E) . Taken together, these data indicate that the pcrG (Δ30-40,Δ60-70) mutation results in selective up-regulation of translocator protein secretion over effector secretion.
Given that both PcrG and PcrV are needed to block effector secretion completely, we explored whether assembly of PcrV at the needle tip influences the pcrG(Δ30-40,Δ60-70) mutant phenotype. We assayed the ability of PcrG(Δ30-40,Δ60-70) to block effector export either in the absence of PcrV or in a strain producing PcrV(F279R), which is specifically defective for assembling at the needle tip (8) . Whereas PcrG(Δ30-40,Δ60-70) was able to control effector export in a strain expressing WT PcrV, deletion of pcrV or prevention of PcrV assembly at the needle tip resulted in complete deregulation of effector secretion (Fig. 3) . Notably, combining PcrG(Δ30-40, Δ60-70) with the Arg85Glu/Arg86Glu double mutation resulted in complete loss of regulatory control, demonstrating that PcrG(Δ30-40,Δ60-70) still needs to associate with the apparatus via the regulatory interaction involving its C terminus (Fig. 3) . Thus, we conclude that either PcrG(Δ30-40,Δ60-70) needs PcrV to assemble at the needle tip to be able to associate with the apparatus, or the pcrG (Δ30-40,Δ60-70) mutation causes a general increase in secretion, not just of translocator proteins, and hence results in highlevel effector secretion when the apparatus is no longer held in the effector secretion "off" conformation in the absence of the needle tip.
PscO Controls Secretion Activity. After identifying PscO as an interaction partner of PcrG, we probed its involvement in secretion regulation by screening for pscO mutations that phenocopy the pcrG(Δ30-40,Δ60-70) mutant phenotype. To this end, we screened for pscO mutants that result in high-level expression of our exoS-lacZ reporter in a strain lacking pcrV, akin to the high-level expression seen when combining pcrG(Δ30-40,Δ60-70) and ΔpcrV (SI Appendix, Fig. S3A) . Notably, this screen does not return misfolded or otherwise null alleles of pscO, because PscO is an essential component of the apparatus. We identified three independent mutations in pscO that resulted in up-regulation of effector secretion in the ΔpcrV strain background: G78E, E88K, and A92T (Fig. 4A) . Although somewhat poorly conserved, 
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these residues cluster together when mapped to the structure of the flagellar homolog FliJ, arguing that the mutations modulate a specific protein-protein interaction (SI Appendix, Fig. S4 ). Interestingly, the residues that we identified are in close proximity to residues identified by Ibuki et al. (34) as being involved in the interaction between FliJ and FlhA, the flagellar homolog of the P. aeruginosa T3SS export apparatus component PcrD. The overlap suggests that our mutations may influence an interaction between PscO and PcrD. Indeed, two-hybrid analysis indicated that none of the pscO mutations affect the PcrG-PscO interaction, suggesting that they influence the interaction between PscO and another apparatus component (Fig. 4B) .
We next examined the ability of these mutants to complement a pscO deletion strain with an intact pcrV allele. Although production of PscO(G78E), PscO(E88K), or PscO(A92T) resulted in complete deregulation of effector secretion in the absence of pcrV, it restored effector secretion control to near-WT levels in a pcrV + strain background (Fig. 4A) . Combining the pscO mutants with a deletion in pcrG did not exacerbate the regulatory effect of the pcrG null (SI Appendix, Fig. S5 ). Expression of these pscO mutants in the exsE deletion background resulted in the hypersecretion of translocator proteins, akin to the hypersecretion seen with the pcrG(Δ30-40,Δ60-70) strain (Fig. 4C) . None of the pscO mutations resulted in effector secretion in the presence of calcium. These data place PcrG and PscO in a pathway for controlling the secretion activity of the apparatus. Moreover, the complete deregulation that we observed when combining the pscO mutants or pcrG(Δ30-40,Δ60-70) with a deletion in pcrV suggests throttling of secretion as the primary means by which PcrG controls protein export in a pcrV null mutant.
PcrG and PscO Control Proton-Motive Force-Dependent Secretion.
Convincing evidence has been provided that protein export via the flagellum relies on the pmf as an energy source. This mechanism has been called into question with regard to virulence-associated T3SSs, however. Although the addition of the protonophore carbonyl cyanide m-chlorophenylhydrazone abolished type III secretion in Yersinia enterocolitica (35), it has been argued that this is related to an indirect effect on ATP levels in the cell or to Sec-dependent export of T3SS apparatus components into the periplasm (27, 30). Interestingly, FliJ, the flagellar homolog of PscO, is thought to control the pmf-dependent export of proteins via the flagellar T3SS (26). This proposed function of FliJ raises the possibility that PcrG and PscO might (A) Control of effector secretion in strain PAO1F ΔpscO ΔexoS::GFP-lacZ and a ΔpcrV derivative, transformed with plasmids encoding the indicated pscO alleles and induced with 10 μM IPTG, was evaluated by β-galactosidase assay. (B) The interaction between PcrG and PscO mutants was assayed using a bacterial two-hybrid system. Protein-protein interaction-dependent activation of the test promoter was determined by the β-galactosidase assay. (C) Secretion of ExoS, ExoT, PopB, PopD, and PcrV was evaluated by Western blot analysis in strain PAO1F ΔexsE ΔfleQ ΔpscO, transformed with plasmids encoding the indicated pscO alleles and induced with 10 μM IPTG. RpoA served as a fractionation control.
not block translocator access to the apparatus but instead may modulate secretion activity by controlling the efficiency with which the T3SS uses the pmf to drive protein export.
If pcrG(Δ30-40,Δ60-70) and pscO mutants allow the T3SS to use the pmf more efficiently, then these mutations should render the export process more resistant to collapsing the pmf. Therefore, we assayed the ability of the pcrG(Δ30-40,Δ60-70) and pscO(E88K) mutations to modulate the sensitivity of translocator export to the addition of pmf inhibitors. The pmf consists of two components, a proton concentration gradient (ΔpH) and a difference in charge between the periplasmic and cytoplasmic faces of the membrane (Δψ). Benzoic acid is a weak acid that collapses the ΔpH component of the pmf. Valinomycin shuttles potassium into the cell, thereby balancing the difference in charge and collapsing the ΔΨ component of the pmf (26). Collapsing the pmf also interferes with T3SS-mediated export of effectors and translocators in P. aeruginosa (SI Appendix, Fig. S6A ).
Disruption of either the pH gradient or membrane charge interfered with translocator secretion in the presence of calcium; however, both pcrG(Δ30-40,Δ60-70) and pscO(E88K) mutations resulted in increased resistance of translocator export to the addition of pmf inhibitors (Fig. 5A ). The collapse of ΔpH and Δψ was monitored using the pH-sensitive GFP derivative pHluorin and the membrane charge-sensitive dye 3,3-Dipropylthiadicarbocyanine iodide [DiSC3(5)], respectively (Fig. 5B) . Neither mutation affected the ability of benzoate and valinomycin to disrupt the pmf.
As a further control, we tested whether increasing secretion by increasing recruitment of translocators to the T3SS could account for the increased resistance to pmf collapse. The export of translocator proteins in the presence of calcium relies on additional translocator export signals (TES) that reside near the chaperone binding site (NTES) and the very C terminus of the protein (CTES) (36). Replacing the CTES of PopB with that of PopD, PopB(D-CTES), resulted in an approximately twofold increase in PopB secretion, presumably by enhancing recruitment of the translocator to the T3SS; however, the increased secretion of PopB(D-CTES) relative to WT PopB did not result in increased resistance of PopB export to pmf collapse (Fig. 5C) . A greater affinity of translocator proteins for the T3SS cannot explain the resistant phenotype of the pscO(E88K) and pcrG(Δ30-40, Δ60-70) mutant bacteria.
To determine whether the differential decrease in translocator export in the WT strain compared with the mutant bacteria is related to a decreased intracellular concentration of ATP, we analyzed the effect of the addition of 12.5 mM sodium benzoate on ATP levels. This concentration of benzoic acid led to a significant reduction in translocator export in the WT bacteria, but not in the pcrG(Δ30-40,Δ60-70) or pscO(E88K) mutant strains. The addition of benzoic acid did not result in any significant decrease in the concentration of intracellular ATP in the WT or pscO(E88K) mutant bacteria (P = 0.30, Student t test). The intracellular concentration of ATP was somewhat reduced in the pcrG(Δ30-40,Δ60-70) mutant strain, providing further evidence that secretion activity is not limited by ATP under the conditions of this assay (SI Appendix, Fig. S6B ). Thus, changes in ATP levels likely cannot account for the change in export. Similarly, dif- pH was determined by producing the pH-sensitive ratiometric GFP derivative pHluorin, and is expressed as the difference in intracellular pH relative to pH 7. Membrane potential was assayed using the membrane potential-sensitive dye DiSC3 (5) and is expressed as fold change in DiSC3 (5) ferences in Sec-dependent export of T3SS components cannot explain our data, given that our treatments did not affect apparatus number (SI Appendix, Fig. S6C ). Treatment of cells with benzoate also did not reduce the export of proteins unrelated to type III secretion in our 30-min treatment period (SI Appendix, Fig. S6A ). Taken together, our findings demonstrate that protein export through the T3SS is dependent primarily on the pmf. Moreover, PcrG and PscO control the activity of the apparatus by modulating the efficiency with which the T3SS uses the pmf for protein export. To confirm that PcrG can be specifically cross-linked to PcrD, we produced the MBP-PcrG(P84C) fusion protein in a strain in which the chromosomal copy of pcrD had been modified to produce PcrD tagged with two copies of the 11-aa VSV-G epitope. We detected a band corresponding to the expected molecular weight of the cross-linked MBP-PcrG-PcrD complex (∼130 kDa) in the presence of the cross-linker (Fig. 6A) . The cross-linked complex could be detected only with MBP-PcrG (P84C), and not with MBP fused to WT PcrG. Some non-crosslinked PcrD copurified with WT MBP-PcrG. The amount was increased in the cross-linked MBP-PcrG(P84C) sample, likely because members of the PcrD family form a nine-membered ring when incorporated into the type III secretion apparatus (37), which would result in non-cross-linked PcrD copurifying with the MBP-PcrG(P84C)-PcrD complex. We also observed a second, higher-molecular weight band in our assays (Fig. 6A) . The nature of the 150-kDa cross-linked protein complex is unclear; however, the 130-kDa band likely represents the true MBPPcrG-PcrD complex and not a breakdown product of the larger complex, given that it can be detected with anti-MBP antibodies and with PcrD tagged at either the N or C terminus. The same cross-linked protein complexes were also evident when PcrD was purified by immunoprecipitation and MBP-PcrG was detected by Western blot analysis (Fig. 6B) .
If the C terminus of PcrG exerts its influence on effector secretion control by stabilizing the effector secretion "off" conformation of PcrD, then triggering of effector secretion would be expected to result in PcrG's dissociation from PcrD. Indeed, triggering of effector secretion by removing calcium from the growth medium prevented formation of the cross-linked MBPPcrG-PcrD complex (Fig. 6C) . Production of MBP-PcrG(P84C) in a strain lacking pcrV, which results in partial deregulation of effector secretion, diminished the level of the MBP-PcrG-PcrD complex. Deletion of pcr1, which completely deregulates effector secretion (SI Appendix, Fig. S8 ), resulted in complete loss of the MBP-PcrG-PcrD complex. Introduction of the R85E/R86E or I95E regulatory mutations into pcrG similarly prevented formation of the MBP-PcrG-PcrD complex. These data suggest that the C terminus of PcrG is released from PcrD on triggering of effector secretion and, conversely, that binding of PcrG to PcrD stabilizes the effector secretion "off' state of the apparatus.
FliJ, the flagellar homolog of PscO, is thought to influence pmf-dependent protein export in the flagellar system by interacting with FlhA, the flagellar PcrD homolog. Thus, we examined whether PscO could be coimmunoprecipitated with PcrD. A fully functional, Myc-tagged version of PscO (SI Appendix, Fig.  S9 ) was coprecipitated with PcrD (Fig. 6D) . The secretion state of the apparatus did not influence the interaction; PscO coprecipitated in both the presence and absence of calcium, as well as in a strain lacking the PopN complex component Pcr1. Notably, deletion of pcrG did not interfere with incorporation of PscO into the secretion apparatus, and neither did the introduction of the regulatory E88K mutation into pscO. These data suggest that PscO is a stable component of the T3SS and exerts its regulatory role through a conformational change rather than through a differential association with the apparatus.
PopN Complex Protein Pcr1 Assembles into a Regulatory Complex
with PcrG and PcrD. Given that PcrG and PscO associate with PcrD, it stands to reason that PcrD is actively involved in the triggering of effector secretion. To further test this hypothesis, we used a selection to identify pcrD mutants that up-regulate effector secretion. To this end, we generated a strain in which a tetracycline resistance gene was integrated at the exoS locus. Triggering of effector secretion in this strain background resulted in tetracycline resistance (SI Appendix, Fig. S3B ). Tetracycline selection was then used to identify pcrD mutant alleles that turn on effector secretion under normally repressive conditions. An important feature of the design is that PcrD is an essential component of the T3SS, and thus mutations that generally disrupt PcrD function will not answer the selection. We isolated three pcrD mutations: Y587H, Q626R, and M667T. Two mutants, Y587H and M667T, partially deregulated effector secretion, akin to the phenotype seen with a pcrG null mutant, whereas the Q626R mutation resulted in complete deregulation of effector secretion (Fig. 7A) . On a threaded model of PcrD, Y587 and M667 are in proximity to each other. Residue Q626 is located near the tip of the ring formed by PcrD, facing the bacterial cytoplasm (Fig. 7B) . Interestingly, Q626 is conserved among virulence-associated T3SSs, but not the flagellum, which has no equivalent to effector secretion control (SI Appendix, Fig. S10 ).
The strong deregulation by pcrD(Q626R) is reminiscent of the deregulation seen when deleting components of the PopN complex (SI Appendix, Fig. S8 ). By analogy to TyeA, which is hypothesized to tether YopN to the apparatus in the Yersinia Ysc T3SS (22, 38), Pcr1 is thought to tether PopN to the apparatus, thereby mediating the regulatory activity of the complex. Thus, we examined whether Pcr1 could be coimmunoprecipitated with PcrD from P. aeruginosa whole-cell extracts. For these experiments, we modified the chromosomal copy of pcr1 to express a functional, HA-tagged version of Pcr1 (SI Appendix, Fig. S9 ). Pcr1 coprecipitated with PcrD (Fig. 7C ). Unlike PcrG, Pcr1 was recovered regardless of the secretion state of the apparatus. Neither removal of calcium from the media nor deletion of pcrG and pcrV prevented the PcrD-Pcr1 association, suggesting that Pcr1 is not removed from the apparatus once effector secretion has been triggered. However, introduction of the pcrD(Q626R) mutation or deletion of pscB encoding a subunit of the PopN chaperone significantly reduced the PcrD-Pcr1 complex (Fig.  7C ). These data argue that Pcr1 is assembled onto PcrD in association with the remainder of the PopN complex, and that this can be influenced by amino acid substitutions at position Q626 of PcrD.
Because both Pcr1 and PcrG appear to engage PcrD, we examined whether these two regulators interact as well. Twohybrid analysis showed that Pcr1 and PcrG interact, but this interaction is abolished in the PcrG(Δ30-40,Δ60-70) mutant protein (SI Appendix, Fig. S11 ). We next tested whether a PcrG (L64C) mutant could be used to trap a complex between Pcr1 and PcrG in P. aeruginosa. Using SMCC, we identified a crosslinked complex between MBP-PcrG(L64C) and Pcr1, indicating that PcrG and Pcr1 are in close proximity to each other (Fig.  7D ). Triggering of effector secretion somewhat diminished the amount of Pcr1 that was cross-linked to PcrG in this assay, it did not completely abolish the interaction, suggesting either that PcrG and Pcr1 also interact when not associated with the apparatus or that PcrG is not released from the apparatus on triggering of effector secretion, even though its C terminus dissociates from PcrD (Fig. 6C ).
Discussion
Control of effector secretion is a central feature of type III secretion systems. Here we investigated the mechanism by which the cytoplasmic regulator PcrG controls effector secretion in the P. aeruginosa T3SS. We found that PcrG controls two aspects of the secretion process: access of effectors to the apparatus and overall secretion activity. These two functions of PcrG are separable. PcrG and the cytoplasmic T3SS component PscO control the secretion by modulating the ability of the T3SS to use the pmf, which also indicates that the pmf is the primary energy source for type III secretion. Access of effectors to the T3SS is controlled by a protein complex that assembles on the inner membrane apparatus protein PcrD and involves the regulators PcrG and Pcr1. High-level secretion of translocator proteins, particularly in mutants that up-regulate secretion activity, demonstrates that effector access is not blocked by plugging the se- cretion channel. Instead, we propose that the regulators block a specific acceptor site for effectors on the T3SS.
Both PcrG and the PopN Complex Assemble on PcrD to Control
Effector Export. We used an in vivo cross-linking approach to identify interaction partners of the cytoplasmic regulator PcrG and isolated a cross-linked complex of PcrG(P84C) bound to the inner membrane component PcrD. Triggering of effector secretion prevented recovery of the PcrG-PcrD complex. PcrG lacking the last 25 amino acids, PcrG(Δ71-95), or with mutations in the C-terminal portion of the protein [e.g., PcrG(R85E/R86E)], was defective in controlling effector secretion, indicating that the C terminus of PcrG needs to contact PcrD to establish effector secretion control. The finding that triggering of effector secretion disrupts the PcrG-PcrD association suggests that PcrD undergoes a conformational change that results in release of PcrG. By extension, we propose that binding of PcrG to PcrD helps stabilize the effector secretion "off" conformation of PcrD. This regulatory function may extend to systems in which the needle tip protein self-chaperones its own export. Thus, the cytoplasmic regulatory function of IpaD, ascribed to its selfchaperoning domain (12, 39) , may involve stabilizing the effector secretion "off" conformation of MxiA. Consistent with the hypothesis that PcrD is directly involved in effector secretion control, we isolated three mutations in pcrD that up-regulate effector secretion. One mutant, Q626R, resulted in complete deregulation of effector secretion, akin to the phenotype of a mutant lacking the PopN complex. Indeed, Pcr1, a component of the PopN complex, could be coprecipitated with PcrD. The association of Pcr1 and PcrD was facilitated by the PopN chaperon PscB/Pcr2, as well as by residue Q626 of PcrD. We suspect that the association between Pcr1 and PcrD that we uncovered here is conserved across the T3SS. In fact, residue Q626 of PcrD, which modulates recruitment of Pcr1 to PcrD, is part of a motif that is highly conserved in virulence-associated T3SSs, but not the flagellar T3SS (SI Appendix, Fig. S10 ). This conservation extends to T3SSs in which the homologs of PopN and Pcr1 are fused, such as MxiC in Shigella spp. (40).
Our data indicate that PcrD serves as a platform on which PcrG and the PopN complex assemble and functions to integrate the regulatory input from these two sets of regulators. Pcr1 also could be cross-linked to PcrG, suggesting that these two proteins are close to each other. PcrD is an excellent target for regulatory control, considering that its homologs have been implicated in the recognition of secretion substrates in both the flagellar system and virulence-associated T3SSs (41-43). Affinities of chaperone/substrate complexes for the C-terminal domain of FlhA appear to dictate the order of export in the flagellar T3SS (44), and deletion of subdomain 2 of MxiA specifically interferes with export of the Shigella translocator protein IpaC (37).
How cytoplasmic regulators control effector secretion is largely unknown. Most models suggest that members of the MxiC/YopN family of proteins form a plug by partially inserting into the T3SS while being tethered to the apparatus (19, 20). Although translocator proteins are exported before effectors, secretion is low, raising the possibility that this export represents stochastic secretion events occurring before the secretion block is established. By identifying mutations that up-regulate translocator secretion without triggering effector export, we have demonstrated that the secretion apparatus is not plugged. Instead, we propose that cytoplasmic regulators block an acceptor site for effector proteins.
Control of pmf-Dependent Protein Export by PcrG and PscO. Until recently, it was assumed that T3SS-associated ATPase plays an important role in energizing export via the T3SS. The ATPase can recognize and unfold secretion substrates (45), and mutants that lack ATPase are type III secretion negative (28-30). This view was challenged by the observation that flagella, which use a type III secretion mechanism to export flagellar subunits, can be assembled in mutants lacking ATPase (FliI) and associated regulatory protein (FliH) in a pmf-dependent manner (24, 25). In a counterargument, it was noted that secretion in the absence of the ATPase is very poor, that the relative contribution of the pmf and ATPase-mediated unfolding to the rate of protein export remains unclear (27), and that the means by which export is energized may differ between the flagellum and virulenceassociated T3SSs (30).
Here we demonstrate that mutations in two T3SS-associated genes, pcrG and pscO, increase secretion activity. This increased activity renders secretion more resistant to collapse of the pmf, suggesting that the increased secretion seen in these mutants is related to more effective utilization of the pmf. Thus, secretion via the virulence-associated T3SS of P. aeruginosa is likewise primarily pmf-dependent. A lack of export in mutants lacking the ATPase and associated regulatory protein, the equivalent of FliI and FliH in the flagellar system, could either reflect an assembly defect of the apparatus or suggest that secretion substrates in these systems are more dependent on unfolding by ATPase to enter the secretion channel.
Our data fit with observations in the flagellar T3SS, where pmf-dependent export has been tied to the association of FliJ, the flagellar homolog of PscO, with FlhA (PcrD) (26). FlhA itself is thought to mediate proton influx in the flagellar system (46). FliJ in turn interacts with the linker connecting the transmembrane domain to the C-terminal cytoplasmic domain of FlhA (41, 42), which conceivably could allow it to modulate proton influx. It stands to reason that PscO similarly interacts with PcrD to control pmf-dependent secretion. PscO did coprecipitate with PcrD, although more work is needed to determine whether this represents a direct interaction. Triggering of effector secretion did not result in dissociation of PscO from PcrD, nor did the activating E88K mutation, suggesting that PscO is stably associated with PcrD. Fig. 8 . Model of effector secretion control. The organization of the T3SS is based on the recent structures of Salmonella and Yersinia T3SS (52, 59). In the effector secretion off state, only translocator proteins are being secreted at a low level, controlled by the influx of protons via PcrD. The PopN complex [green: PopN, PscB (B), Pcr2 (2), and Pcr1 (1)] blocks access of effectors to the T3SS and is tethered to the apparatus via the interaction of Pcr1 with PcrD. PcrG (yellow) stabilizes the PopN complex and controls the activity of the apparatus via an interaction with PcrD. PscO (blue) binds to the linker domain that connects the inner membrane domain of PcrD to the C-terminal cytoplasmic domain and helps control secretion activity by modulating proton flow through PcrD. In the effector secretion on conformation, PopN is secreted, allowing effectors to access the secretion apparatus via the sorting platform consisting of PscK, PscL, and PscQ (pale purple). The activity of the apparatus is up-regulated, likely through a conformational change in PcrD and PscO, which allows for increased influx of protons.
Separation of activity control and effector access has been observed in other T3SSs, although it has not been interpreted in these terms, and the mechanistic underpinnings remain obscure. Deletion of mxiC, encoding the Shigella spp. homolog of PopN, results in premature secretion of effector proteins, but at a low level compared with complete induction of the system by Congo red (6) . Slow-secreting, "constitutive on" needle-subunit mutants in Shigella similarly turn on effector secretion without the upregulation of secretion rate seen in the presence of Congo red or in strains lacking the needle tip-associated translocator proteins IpaB and IpaD (47, 48). Conversely, small deletions in the needle tip protein IpaD can selectively up-regulate secretion of early export substrates, including the pore-forming translocator proteins IpaB and IpaC, but not late effectors (7) . Because IpaB and IpaC proteins are secreted at low levels before triggering of effector secretion in a process termed leakage, these ipaD mutants modulate the secretion activity.
Although control of secretion activity and specificity likely are general features of T3SSs, the mechanism of activity control may vary among systems. In Shigella, for example, control of secretion activity appears to involve proteins associated with the needle tip, IpaD and IpaB. Perhaps here secretion is throttled by the tip structure through the formation of a plug that is removed by the insertion of IpaB into the host cell membrane (48). Ultimately, all type III secretion systems are faced with the same conundrum, highlighted by our work: the need to minimize the export of proteins before cell contact, allowing secretion of just enough translocators to permit sensing of host cell contact, versus the need to deliver a bolus of effectors quickly once effector secretion is triggered. The mechanism by which this problem is solved may vary among species.
A Model for Effector Secretion Control. Our data point to a model in which the access of effectors to the T3SS and secretion activity are controlled through PcrD and associated regulatory proteins (Fig. 8) . We propose that the PopN complex assembles on the PcrD ring to prevent access of effectors to the T3SS without blocking the secretion channel. PcrG likely exerts its control by stabilizing the effector secretion "off" conformation of PcrD. On triggering of effector secretion, PopN is exported via the T3SS, thereby freeing the acceptor site for effectors. We have represented the PopN complex as spanning PcrD and ATPase, because PopN homologs require a secretion signal to prevent effector export (13, 19 ) and the secretion signal can mediate a specific interaction with the ATPase (13). Intriguingly, a F234S mutant of YopN did not require its secretion signal or chaperone binding domain to block effector export, suggesting that binding to the acceptor site precedes engagement of the ATPase (19). A better understanding of how effector export is prevented without interfering with translocator secretion will require a more detailed view of how export substrates are recruited to the apparatus. Identifying the interactions of secreted proteins with PcrD, as well as the temporal order with regard to the sorting platform (49) and ATPase (13, 45, 50), will be key in this endeavor.
Triggering of effector secretion also results in increased pmfdependent secretion activity. The secretion activity is controlled through the concerted action of PcrG and PscO. Given that PscO does not dissociate from the apparatus on triggering of effector secretion, its effect on secretion activity likely involves a more subtle alteration in the conformation and activity of the proton channel. We depicted PscO as binding to the linker between the N-terminal transmembrane domain and cytoplasmic domain of PcrD. This location is in line with its role in controlling proton flux through the T3SS, but does not correspond with the recently proposed location of FliJ inserted in the flagellar ATPase (51). Recent structural findings have called this localization into question, however, because the ATPase is too far away from the FlhA linker domain to allow FliJ to interact with both (52). No density corresponding to FliJ could be discerned protruding from the ATPase either, but this may be related to the small size of the protein. FliJ promotes assembly of the ATPase hexamer in vitro (51). FliJ, as well as its homologs, also can interact with chaperone proteins for select secretion substrates (53-56); thus it may have three roles in T3SS function, each at a separate stage of the export process: assembly of the ATPase, facilitation of pmfdependent protein export, and a chaperone sink.
In conclusion, we have presented evidence that protein export via T3SSs is regulated at the levels of both secretion activity and specificity. The inner membrane component PcrD serves as a platform on which regulators assemble to mediate their control. Cytoplasmic regulators do not plug the secretion channel; instead, PcrG stabilizes the effector secretion "off" conformation of the T3SS, and the PopN complex likely blocks an acceptor site for effectors. Secretion is energized by the pmf, and the secretion activity is modulated through the action of PcrG and PscO, which control the coupling of protein export to the pmf.
Materials and Methods
Strains, Plasmids, and Culture Conditions. Details of strain and plasmid construction are provided in SI Appendix. The E. coli strains used in this study were grown in LB (10 g of tryptone, 5 g of yeast extract, and 10 g of NaCl per L). P. aeruginosa was cultured in modified LB (LB-MC medium: 10 g of tryptone, 5 g of yeast extract, and 11.7 g of NaCl per L, supplemented with 10 mM MgCl 2 and 0.5 mM CaCl 2 ). Where indicated, effector secretion was triggered by removing calcium from the medium through the addition of EGTA (5 mM final concentration).
β-Galactosidase Activity Assay. Cultures were grown at 37°C to early log phase in LB-MC medium, after which 1 mL of culture was added to 1 mL of prewarmed LB-MC medium (+Ca 2+ condition) and another 1 mL of culture was added to 1 mL of prewarmed LB-MC medium with 10 mM EGTA (5 mM final concentration; −Ca 2+ condition). The cultures were then incubated for an additional 2 h at 37°C before being placed on ice for 10 min. Cells were permeabilized with chloroform and SDS, and β-galactosidase activity was measured as described previously (57). Activities are reported as average ± SD of three independent replicates.
Protein Secretion Assay. Overnight cultures were diluted and grown to midlog phase at 37°C, after which the cultures were split and the bacteria pelleted. The cell pellets were resuspended in prewarmed LB-MC medium alone (+Ca 2+ condition) or in LB-MC medium with 5 mM EGTA (−Ca 2+ condition) and incubated for 30 min at 37°C, then chilled on ice. The bacteria were then pelleted by centrifugation, and supernatant proteins were precipitated using trichloroacetic acid. Cell pellet and supernatant fractions were separated by SDS/PAGE, and proteins of interest were detected by Western blot analysis using a chemiluminescent detection system. Images were acquired by either exposing blots to film and scanning the film or using a GE ImageQuant LAS 4000 digital imaging system. Images were processed with the Levels function in Adobe Photoshop applied to the whole image before cropping.
Site-Specific Cysteine Cross-Linking. Cultures were grown at 37°C to midlog phase in 200 mL of LB-MC medium. The bacteria were then pelleted by centrifugation and resuspended in cross-linking buffer (PBS with freshly prepared 1 mM PMSF and 0.5 mM SMCC). For cultures grown in the presence of calcium, the cross-linking buffer was supplemented with 0.5 mM CaCl 2 .
The cell suspensions were incubated at room temperature in the dark for 30 min, after which the bacteria were pelleted, washed once in MBP purification buffer (20 mM Tris pH 7.5, 100 mM NaCl, 10 mM β-mercaptoethanol, 1 mM EDTA, 1 mM PMSF, and 0.5% Nonidet P-40), and resuspended in 1 mL of MBP purification buffer before being lysed by sonication. 31 
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Chemicals and antibodies
Antibodies against PopB, PopD, PcrV, ExoS, ExoT, and maltose-binding protein (MBP) were generated in rabbits by commercial services (Covance). Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) was purchased from Thermo Scientific. Anti-HA tag antibody (mouse origin) conjugated with horse-radish peroxidase was purchased form Roche Diagnostics. Anti-VSVG tag antibody (mouse origin) and valinomycin were purchased from Sigma-Aldrich. Anti-VSVG tag antibody (rabbit origin) was purchased from Bethyl Laboratories, Inc.. Mouse anti-RpoA monoclonal antibody was purchased from Neoclone. Potassium benzoate was purchased from Alfa Aesar. Amylose-resin was purchased from New England Biolabs, Inc. Protein A/G plus-agarose was purchased from Santa Crutz Biotechnology, Inc. AntiMyc antibody (rabbit origin) was purchased from Novus Biologicals.
Strain and plasmid construction
All strains and plasmids used in this study are listed in Table S1 and Table S2 , respectively. Mutations in the chromosome of P. aeruginosa were introduced by allelic exchange using plasmid pEXG2 (1). Plasmids were mated into P. aeruginosa using E. coli SM10 λpir as a donor and cointegrates were isolated by selection on LB plates with gentamicin (30 µg/ml) and triclosan (5 µg/ml). Cointegrates were then restreaked on the same plate and an isolated colony was inoculated into 2ml of low salt LB (10g/l tryptone, 5 g/l yeast extract, 5 mM NaCl, 10 mM MgCl 2 and 0.5 mM CaCl 2 ). Once the culture had reached early log (OD 600 0.1-0.3) 100 µl of the culture was plated on sucrose plates (10 g/l tryptone, 5 g/l yeast extract, 50 g/l sucrose) and incubated overnight at 30°C. Colonies were tested for the loss of gentamicin resistance, indicating loss of the allelic exchange vector via a second recombination event and the resultant gentamicin sensitive isolates were tested for retention of the mutation on the chromosome by PCR. Plasmids were constructed using standard molecular biology techniques. PCR products were amplified using the primers listed in Table S3 using Pfx50 polymerase (Invitrogen) in the presence of 5% DMSO. Where needed, mutations were introduced by cross-over PCR (2) .
Flow Cytometry
Bacteria were diluted 1:300 from overnight cultures into high salt LB-MC medium supplemented with 5mM EGTA as indicated. The bacterial cultures were grown at 37 o C to mid-log phase. 1 ml of culture was removed to a microcentrifuge tube and the cells were pelleted by centrifugation at 4,000 rpm for 4 minutes, washed once in PBS-SMC (PBS with 0.1% saponin, 10 mM MgCl 2 , 0.5 mM CaCl 2 ) and resuspended in 500 µl of the same buffer. Cells were fixed by adding 500 µl 4% paraformaldehyde, mixed by inversion and incubated at room temperature for 20 minutes. The remaining crosslinker was quenched by the addition of 50 µl 1M Tris.Cl (pH 7.5) and the cell suspension was again mixed by inversion, incubated for 5 minutes at room temperature, and cells were pelleted at 13,000 rpm for 3 minutes, washed 1 × with PBS-SMC and 1 × with PBS-MC(containing Mg 2+ and Ca 2+ , as indicated for PBS-SMC but no saponin) and resuspended in PBS with 2% goat serum and 2% BSA. Blocking was performed for 30 minutes on ice at which point the bacteria were pelleted and washed twice with PBS-MC for 15 minutes on ice. 100 µl of primary antibody solution was added (anti-PcrV antibody, 1:100 dilution in blocking buffer) and the tubes were rocked for 1 hour at 4 o C. Following primary antibody staining, cells were washed twice with PBS-MC for 15 minutes each on ice, followed by the addition of 100 µl of secondary antibody solution (goat-anti-rabbit-Alexa Fluor 647 conjugated antibody (Invitrogen), diluted 1:1000 in blocking buffer). The tubes were wrapped in aluminum foil and rocked at 4°C for 1 hour. The bacteria were then pelleted, washed twice with PBS-MC and resuspended in 50 µl of PBS. For each sample, 10 µl of the labeled bacteria were diluted into 1ml of PBS in a 5 ml polystyrene tube (BD Falcon) and analyzed by flow cytometry (Becton Dickinson SORP LSRFortessa, FacsDiva v6.2; 640nm coherent laser was used for excitation of Alexa Fluor 647 and emission was detected with a 670/30 bandpass filter) at the CFAR Immune Function Core Facility at Case Western Reserve University. Data were analyzed using FlowJo v7.6.4 software (Treestar, Ashland, OR). Several wash steps were tested to optimize removal of non-specifically adhered PcrV without permeabilizing the bacteria. To this end, strains PAO1F, PAO1F ∆fleQ ∆exsE, PAO1F ∆fleQ ∆exsE ∆pscD, as well as PAO1F ∆pcrV2, which had been pre-incubated with purified PcrV (50 ng/ml) for 10 minutes at room temperature, were stained using the procedure outlined above, with four different wash buffers (instead of the PBS-SMC, which was used in the experiment depicted in Figure S2 ): PBS with 2% goat serum/BSA, PBS-MC with 0.1% Tritonx-100, PBS-MC with 0.1% saponin or PBS-MC with LPS (25 ug/ml). All strain/wash combinations were analyzed by flow cytometry to determine which condition resulted in the absence of non-specific staining in the PcrV-treated PAO1F ∆pcrV2 sample (removal of non-specifically adhered PcrV) as well as lack of staining in the PAO1F ∆fleQ ∆exsE ∆pscD strain, which expresses high levels of PcrV, but does not secrete the protein (lack of permeabilization/stain is specific to surfacelocalized protein). Antibody titer: The primary anti-PcrV antibody was titered first. 8 titer points were tested while keeping the secondary antibody constant (1:250). Once the optimal primary antibody concentration was determined, the secondary antibody was titered (keeping the determined primary concentration constant (1:150).
ß-galactosidase activity assay -exoS reporter strains Overnight cultures were diluted 1:300 into 3 ml of LB-MC medium. After 2 hours of incubation at 37 °C, 1 ml of culture was added to 1 ml of pre-warmed LB-MC medium (+ Ca 2+ condition) and another 1 ml of culture was added to 1 ml of pre-warmed LB-MC medium with 10mM EGTA (5 mM final concentration, -Ca 2+ condition). The cultures were then incubated for an additional 2 hours at 37 °C before being placed on ice for 10 minutes. Cells were permeabilized with chloroform and SDS and the ß-galactosidase activity was determined as described previously (3) . Activities are reported as averages of three independent replicates ± standard deviation.
E. coli bacterial two-hybrid analysis
The λ cI/RNA polymerase α-subunit bacterial two-hybrid system was used to determine the interaction between PcrG and the T3SS components (4). The indicated T3SS components were fused to the Cterminus of the α subunit of RNA polymerase and PcrG was fused to the C-terminus of λ cI. Plasmids encoding the fusion proteins were transformed into the E. coli strain, BN469, which harbors a lacZ reporter gene controlled by a lac core promoter with adjacent λ operator site, allowing binding of the cI fusion protein. Interaction between the fusion partners leads to recruitment of RNA polymerase to the test promoter and activation of lacZ transcription. Overnight cultures were diluted 1:300 into 3 ml of LB medium. After 2 hours of incubation at 37 °C, 1 ml of culture was added into 1 ml of pre-warmed LB medium and another 1 ml of culture was added into 1 ml of pre-warmed LB medium with IPTG (the final concentration is noted in the figure legend). The cultures were incubated at 37 °C for an additional 2 hours. Then the cultures were put on ice for 10 minutes and lacZ expression was determined by β-galactosidase activity assay (3).
pscO and pcrD mutant library screens pscO and pcrD ORFs were amplified by error-prone PCR with 1 mM dTTP, 1 mM dCTP, 0.1 mM dATP, 0.1 mM dGTP and Taq DNA polymerase (Choice Taq blue, Denville) and cloned into pPSV35 and pPSV39 expression vectors, respectively, which confer gentamicin resistance. The plasmids were transformed into DH5α to generate the mutant libraries, and the size of the libraries was estimated by plating a portion of the transformation mix on LB gentamicin plates. Religation was estimated by plating the empty vector control ligation transformation mix. The religation rates for pscO and pcrD libraries were 5% and 6%, respectively. The size of the pscO library was 78,000 transformants and the size of the pcrD library was 48,000 transformants. For isolating pscO mutants phenocopying the pcrG(∆30-40,∆60-70) mutant phenotype, plasmid DNA from the pscO mutant library was transformed into strain PAO1F ΔpscO ∆pcrV ΔexoS::GFPlacZ, and the transformed bacteria were plated on LB-MC agar plates containing X-gal (10 g/l tryptone, 5 g/l yeast extract, 11.7 g/l NaCl, 10 mM MgCl 2 , 0.5 mM CaCl 2 , 15 g/l agar, 100 µg/ml X-gal, 30 µg/ml gentamicin) ( Figure S3A ). pscO mutants phencopying the phenotype of pcrG(∆30-40,∆60-70) mutant formed dark blue colonies and were re-streaked on X-gal plates to confirm the dark blue phenotype. The plasmids were isolated, retransformed to confirm the mutant phenotype and sequenced to identify the mutations in the pscO ORF. For isolating pcrD mutants up-regulating effector secretion, plasmid DNA purified from the pcrD mutant library was transformed into strain PAO1F ΔpcrD ΔexoS::tetR, in which the chromosomal exoS gene was replaced by a tetracycline resistance gene. The transformed bacteria were plated on LB-MC agar plates containing tetracycline (10 g/l tryptone, 5 g/l yeast extract, 11.7 g/l NaCl, 10 mM MgCl 2 , 0.5mM CaCl 2 , 15g/l agar, 250µg/ml tetracycline). pcrD mutants activating effector secretion in the presence of calcium expressed the tetracycline resistance gene and formed colonies on the LB-MC agar plates containing calcium and tetracycline ( Figure S3B ). Tetracycline resistant clones were restreaked on tetracycline plates. The plasmid DNA of the tetracycline resistant mutants was purified and retransformed into strain PAO1F ΔpcrD ΔexoS::GFP-lacZ to assay effector secretion control and confirm the mutant phenotype. The mutant plasmids were then sequenced to identify the mutations in the pcrD ORF. After the mutations in pscO and pcrD were identified, new expression plasmids with the mutations were artificially constructed using synthetic primers encoding the identified mutations, but using a different codon to confirm that the mutant phenotype is linked to the nature of the amino acid substitution, and transformed into P. aeruginosa to confirm the phenotype.
Measuring ATP levels
Overnight cultures of P. aeruginosa were diluted 1:300 into 6 ml of fresh LB-MC medium and incubated at 37 °C for 3 hours to mid-log phase. Then 4 ml of culture were divided in two microcentrifuge tubes and spun down, the supernatants were removed and one cell pellet was resuspended in 2 ml pre-warmed LB-MC medium without potassium benzoate, the other in 2 ml pre-warmed medium with 12.5 mM potassium benzoate. The cultures were incubated at 37 °C for an additional 30 minutes. Sample preparation for determination of ATP levels was based on the method described by Bakker and Mangerich (5) . 500 µl of culture normalized to the same OD 600 were mixed with 500 µl of cold 12% HClO 4 in 5 mM Na 2 HPO 4 and incubated on ice for 30 minutes. The samples were then centrifuged at 5,000 rpm, 4°C for 10 minutes, and 500 µl of supernatant was mixed with 300 µl of cold neutralizing buffer (2 M KOH/0.3 M MOPS). The samples were frozen at -20°C, then thawed and centrifuged at 10,000 rpm, 4°C for 5 minutes. The ATP content in the supernatant was measured using a luciferase-based ATP determination kit (Molecular probes, Invitrogen detection technologies). The ATP contents were compared and presented as percentage of the ATP level in wild type P. aeruginosa strain without potassium benzoate treatment. The results presented in Figure S6 represent the average of at least three independent experiments ±SD.
Protein secretion assay
Overnight cultures were diluted 1:300 into 6 ml of fresh LB-MC medium and incubated at 37 °C for 3 hours (mid-log phase, OD 600~0 .4). Then 4 ml of culture were divided in two microcentrifuge tubes, the bacteria were pelleted and supernatants removed. One cell pellet was resuspended in 2 ml pre-warmed LB-MC medium (+Ca 2+ ), the other in 2 ml pre-warmed LB-MC with 5mM EGTA (-Ca 2+ ). The cultures were then incubated at 37 °C for an additional 30 minutes and subsequently placed on ice for 10 minutes. Bacteria from 1 ml of each culture were pelleted and 0.5 ml of the supernatant was transferred to a fresh microcentrifuge tube, the remaining supernatant was discarded. Supernatant proteins were precipitated with trichloroacetic acid (TCA, 10% final conc.), washed with acetone and dried. Cell pellets and TCA precipitated supernatant samples were resuspended in 1x SDS sample buffer and normalized to an OD 600 of 10. Proteins of interest were detected by Western blot using a horseradish peroxidase conjugated secondary antibody and a chemiluminescent detection system, either by exposing the blots to film or using a GE ImageQuant LAS4000 digital imaging system. Band intensities were quantitated using ImageJ software (6) .Secretion efficiency was calculated as: 100*[supernatant protein]/[total protein]. For the secretion assays with PMF inhibitors (potassium benzoate and valinomycin+200 mM KCl), the inhibitors were added for the 30-minute incubation after pelleting the bacteria and resuspending them in LB-MC.
Site-specific cysteine crosslinking
Overnight cultures were diluted 1:100 into 200 ml of fresh LB-MC medium and incubated at 37 °C for 3 hours (OD 600~0 .5-0.6). After normalizing the OD 600 of the cultures, the bacteria were pelleted by centrifugation and resuspended in the crosslinking buffer [1x PBS (1.06 mM KH 2 PO 4 , 155.17 mM NaCl, 2.97 mM Na 2 HPO 4 , pH 7.4), 1 mM PMSF and 0.5 mM Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)], both freshly prepared. For cultures grown in the presence of calcium, the crosslinking buffer was supplemented with 0.5 mM CaCl 2 . The cell suspensions were incubated at room temperature in dark for 30 minutes. The bacteria were then pelleted, washed once in MBP-purification buffer [20 mM Tris pH 7.5, 100 mM NaCl, 10mM ß-mercaptoethanol, 1 mM EDTA, 1 mM PMSF, 0.5% NP-40] and resuspended in 1 ml MBP-purification buffer before being lysed by sonication.
Amylose resin purification
Crosslinked cell suspensions in MBP purification buffer were sonicated 4 times with 30 second interval at power level 3.5 with Misonix sonicator 3000. The cell lysate was centrifuged at 13,200 rpm 4°C for 10 minutes to remove cell debris. 20 µl of cell lysate were removed to a fresh tube and mixed with 20 µl of 4x SDS sample buffer and 40 µl of water as input control. 900 µl of cell lysate were transferred to a fresh tube and mixed with amylose-resins washed 3 times with MBP purification buffer. The mixtures were incubated at 4 °C on a rocker for 1 hour. Then the amylose-resin was pelleted by centrifugation and washed 3 times with MBP purification buffer. Bound proteins were eluted with two 450 µl washes of elution buffer (20mM Tris pH 7.5, 200 mM NaCl, 10 mM ß-mercaptoethanol, 1 mM EDTA, 1 mM PMSF, 0.5% NP-40, 10 mM maltose). The combined elution samples were precipitated with 100 µl of 100% TCA (final conc. 10%). Precipitated proteins were resuspended in 40 µl of 1x SDS sample buffer.
Immunoprecipitation P. aeruginosa cell suspensions in MBP purification buffer were sonicated 4 times with 30 second interval at power level 3.5 with Misonix sonicator 3000. The cell lysate was centrifuged 13,200 rpm 4°C for 10 minutes to remove cell debris. 20 µl of cell lysate were removed to a fresh tube and mixed with 20 µl of 4 xSDS sample buffer and 40 µl of water as input control. 900 µl of cell lysate were transferred to a fresh tube and pre-cleared for 15 minutes at 4°C by incubating with protein A/G agarose beads washed with MBP purification buffer. The beads were removed by centrifugation at 8,000 rpm for 2 minutes and the supernatant was transferred to a new tube. α-VSV-G antibodies were added to each tube and the supernatants were incubated at 4°C on a rocker for 15 minutes. Then protein A/G agarose beads, washed with MBP purification buffer, were added to each tube and the mixtures were rocked for an additional 45 minutes at 4°C. The beads were then pelleted, washed 3 times with MBP purification buffer and resuspended in 40μl 1x SDS sample buffer. The samples were incubated at 55°C for 10 minutes to elute proteins bound to the beads, then the samples were vortexed, centrifuged, and supernatants were collected as elution fraction.
Protein overexpression and purification by Ni-NTA chromatography
His-tagged versions of pcrG, pcrG(∆30-40,∆60-70) and pcrG(∆71-95), as well as a Myc-tagged version of pscO were overexpressed in E.coli BL21(DE3) Codon+ RP-(Stratagene). The bacteria were grown overnight in 2xYT medium with 30 µg/ml carbenicillin and subsequently diluted 1:200 into fresh 2xYT medium [50 ml of the His-pcrG cultures and 200 ml for the pscO-myc culture) and grown at 37°C for 2.5 hours. At this point, protein production was induced for one hour by adding IPTG to the culture [100 µM, final concentration]. The cells were pelleted and resuspended in binding buffer (50 mM NaH 2 PO 4 , pH 8.0, 500 mM NaCl, 10 mM imidazole, 1 mM PMSF) and normalized to a final OD 600 of 25. Resuspended cells were lysed by sonication and centrifuged at 13,200 rpm for 10 min. 20 µl of supernatant were taken and mixed with 17.5 µl of H 2 O and 12.5 µl of 4x SDS sample buffer to make the 50 µl of input control samples. 900 µl of supernatant from each His-tagged PcrG lysates were mixed with 900 µl of supernatant from PscO-Myc lysate and incubated on a rocker at 4°C for 90 minutes. Mixtures of His-tagged PcrGs and PscO-Myc lysates were then incubated with Ni-NTA beads (Qiagen) on a rocker at 4°C for 1 hour to allow binding of PcrG to the nickel resin. The beads were washed with binding buffer and bound proteins were eluted with two 540µl aliquots of elution buffer (50 mM NaH 2 PO 4 , pH 8.0, 500 mM NaCl, 500 mM imidazole, 1 mM PMSF). Eluted proteins were precipitated with 120 µl of 100% TCA (10% final concentration), pelleted and washed with acetone before being resuspended in 50 µl 1x SDS sample buffer. 15 µL of each sample were separated by SDS-PAGE and proteins were detected by coomassie stain or western blot.
Intracellular pH measurement
Strains PAO1F ∆exsE ∆fleQ, PAO1F ∆exsE ∆fleQ pscO(E88K) and PAO1F ∆exsE ∆fleQ pcrG(∆30-40,∆60-70) were transformed with plasmid pP40-pHluorin, which encodes a pH-sensitive, ratiometric GFP derivative (7) . The bacteria were cultured overnight in LB-MC with 30 µg/ml gentamicin, diluted 1:200 diluted into fresh LB-MC with 30 µg/ml gentamicin and grown to mid-logarithmic phase. The bacteria were then pelleted and resuspended in 200 mM sodium phosphate buffer (pH 7) with different concentrations of potassium benzoate or valinomycin and incubated for 30 minutes before measuring the fluorescence emission of pHluorin (530 nm emission) excited at either 410 or 470 nm using a SpectraMax M2 fluorescence spectrophotometer (Molecular Devices). A standard curve was established by resuspending bacteria in 200 mM sodium phosphate buffer (pH 6, 7 and 8) in the presence of 40 mM potassium benzoate, and used to calculate the intracellular pH of the inhibitor-treated samples. Data is presented as ∆pH compared to the external pH of the medium (pH 7).
Change of membrane potential
The change in membrane potential of inhibitor-treated P. aeruginosa was detected using the fluorescent dye DiSC3(5) (AnaSpec, Inc.) based on the method described by Zhang et al. (8) . The bacteria were cultured overnight in LB-MC, then diluted 1:200 in fresh LB-MC and grown to mid-logarithmic phase. Cells were then pelleted, washed and resuspended in 5 mM HEPES buffer, pH 7.7, to an OD 600 of 0.1. DiSC3 (5) dye (final conc. 0.4 mM) was added to the cells and the suspension was incubated at room temperature for 20 minutes, at which point 100 mM KCl (final concentration) was added. The cells were then treated with potassium benzoate or valinomycin and incubated for an additional 30 minutes. Disruption of membrane potential resulted in enhanced DiSC3(5) fluorescence, which was detected using a SpectraMax M2 fluorescence spectrophotometer (Molecular Devices, excitation 622 nm, emission 670 nm). Data is presented as fold increase in fluorescence intensity relative to wild-type bacteria without inhibitor treatment.
Protein sequence alignments
Protein sequences were aligned using the MacVector (MacVector, Inc.) software package and the ClustalW algorithm (9) . Subdomains of PcrD were assigned according to the published domain structure of the S. flexneri homolog MxiA (10) . FliJ residues involved in mediating the interaction with FlhA, identified by Ibuki et al. (11), were mapped onto the published crystal structure of FliJ (12) . GenBank accession numbers for aligned proteins: (1) pPSV37 colE1 origin, gentR, PA origin, oriT, lacUV5 promoter, lacIq, stops in every reading frame preceding the MCS and T7 terminator following the MCS (relative to the lacUV5 promoter) (17) pPSV40 colE1 origin, with gentamicin resistance gene (gentR), PA origin, multiple cloning site and no promoter allelic exchange vector designed to introduce the F279!R mutation into pcrV (17) pEXG2-∆pcrGV2 allelic exchange vector designed to delete pcrG and pcrV starting at codon 6 of pcrG and ending at codon 180 of pcrV (17) pEXG2-∆exoS::GFP-lacZ allelic exchange vector which deletes exoS and inserts translationally coupled versions of GFP and lacZ in its place Table S3 Primer Figure S1 . The P. aeruginosa strain with an exsE deletion assembles more T3SS apparatus at bacterial surface than wild-type bacteria in the presence of calcium (effector secretion off) and has equal number of the apparatus with/without calcium in the medium. Related to Figure  1 of the manuscript. Assembled T3SS were quantified by staining bacteria grown under the indicated culture condition with an affinity purified antibody directed against the needle-tip protein PcrV and an Alexa-fluor 647 conjugated secondary antibody. Stained bacteria were then analyzed by flow cytometry. All the P. aeruginosa strains tested are in ∆fleQ background to prevent any nonspecific secretion of PcrV through the flagellar secretion system. The P. aeruginosa strain lacking the pscD gene, which encodes an essential inner membrane component of the T3SS, served as a T3SS null control. EGTA was added to remove Ca 2+ from the culture medium. 10,000 single cell events were analyzed for each strain and condition and the peak height was normalized during the overlay for clarity. ! and pscO(E88K) mutant derivatives, with or without 12.5mM potassium benzoate treatment, was determined by luciferase assay. ATP levels were compared to the wild type control without benzoate treatment and represent mean of 3 independent experiments ± SD. C) Assembled T3SS were quantified by staining bacteria grown under the indicated culture condition with an affinity purified antibody directed against the needle-tip protein PcrV and an Alexa-fluor 647 conjugated secondary antibody. Stained bacteria were then analyzed by flow cytometry. All the P. aeruginosa strains tested are in ∆fleQ background to prevent any non-specific secretion of PcrV through the flagellar secretion system. Strains were grown up and treated as for the secretion assays reported in Fig. 5 . 10,000 single cell events were analyzed for each strain and condition and the peak height was normalized during the overlay for clarity. The primary antibody was omitted in the secondary control samples.! 
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Pcr1
Figure S11. Two-hybrid analysis of the PcrG-Pcr1 interaction. Related to Figure 7 of the manuscript. The interaction between PcrG and Pcr1 was monitored using the E. coli RNA polymerase α/lambda cI, bacterial two-hybrid system. Expression of the indicated α-and cIfusion proteins was induced by adding 50 µM IPTG to the medium. Interaction-dependent recruitment of RNA polymerase to the test promoter results in activation of lacZ expression, which was assayed by ß-galactosidase assay. !
